
Japan Approves First-in-Class Treatment for Narcolepsy and OSA-Related Excessive Daytime Sleepiness
A newly approved histamine H3 receptor antagonist/inverse agonist offers a non-scheduled treatment option for excessive daytime sleepiness in Japanese patients.


